TaiGen Biopharmaceuticals Holdings Limited Stock
Equities
4157
KYG866171005
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.2 TWD | -0.98% | +1.00% | -.--% |
Sales 2022 | 36.23M 1.12M | Sales 2023 | 123M 3.8M | Capitalization | 10.91B 337M |
---|---|---|---|---|---|
Net income 2022 | -237M -7.31M | Net income 2023 | 137M 4.23M | EV / Sales 2022 | 294 x |
Net cash position 2022 | 860M 26.55M | Net cash position 2023 | 963M 29.73M | EV / Sales 2023 | 80.8 x |
P/E ratio 2022 |
-48.5
x | P/E ratio 2023 |
80
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50% |
1 day | -0.98% | ||
1 week | +1.00% | ||
1 month | +0.33% | ||
6 months | -5.30% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Huang
CEO | Chief Executive Officer | - | 18-12-16 |
Richard Lue
DFI | Director of Finance/CFO | - | 16-03-31 |
Ming-Chu Hsu
BRD | Director/Board Member | - | 01-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shou-Chuan Ho
BRD | Director/Board Member | - | 13-04-28 |
Hong Jen Chang
BRD | Director/Board Member | 68 | 13-03-31 |
Sheng Fu Yu
BRD | Director/Board Member | 79 | 19-06-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 15.2 | -0.98% | 1,168,309 |
24-05-30 | 15.35 | +1.66% | 2,630,814 |
24-05-29 | 15.1 | +0.33% | 1,231,392 |
24-05-28 | 15.05 | +0.33% | 1,520,340 |
24-05-27 | 15 | -0.33% | 1,235,987 |
End-of-day quote Taipei Exchange, May 30, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-.--% | 335M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- 4157 Stock